Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors

ACS Chemical Biology

Volumn 11, Issue 11, 2016, Pages 3214-3225

  Singh, Anju ^a   Venkannagari, Sreedhar ^a   Oh, Kyu H ^a   Zhang, Ya Qin ^b   Rohde, Jason M ^b   Liu, Li ^b   Nimmagadda, Sridhar ^c   Sudini, Kuladeep ^a   Brimacombe, Kyle R ^b   Gajghate, Sachin ^a   Ma, Jinfang ^a   Wang, Amy ^b   Xu, Xin ^b   Shahane, Sampada A ^b   Xia, Menghang ^b   Woo, Juhyung ^c   Mensah, George A ^d   Wang, Zhibin ^a   Ferrer, Marc ^b   Gabrielson, Edward ^c   Li, Zhuyin ^b   Rastinejad, Fraydoon ^e   Shen, Min ^b   Boxer, Matthew B ^b   Biswal, Shyam ^a,c   more..

^a Johns Hopkins University   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CAP N COLLAR BASIC LEUCINE ZIPPER PROTEIN; CARBOPLATIN; DOXORUBICIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; ML 385; ONCOPROTEIN; PACLITAXEL; PROTEIN V MAF; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NEH1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; V MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOGUE G PROTEIN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL SPECIFICITY; CLONOGENIC ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; GENE EXPRESSION; GENE TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG VOLUME; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; MOLECULE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; REGULATORY DNA SEQUENCE; TUMOR GROWTH; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2;

EID: 84996836200     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.6b00651     Document Type: Article

References (37)

1. (2013) Cancer Facts and Figures 2013, American Cancer Society, Atlanta, GA.
2. Hirsh, V. (2010) Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach Curr. Oncol. 17, 13-23
3. Tsvetkova, E. and Goss, G. D. (2012) Drug resistance and its significance for treatment decisions in non-small-cell lung cancer Curr. Oncol 19, S45-51 10.3747/co.19.1113
4. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu. Rev. Pharmacol. Toxicol. 47, 89-116 10.1146/annurev.pharmtox.46.120604.141046
5. Singh, A., Happel, C., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., Boros, L. G., Gonzalez, F. J., Gabrielson, E., Wong, K. K., Girnun, G., and Biswal, S. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis J. Clin. Invest. 123, 2921-2934 10.1172/JCI66353
6. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., and Motohashi, H. (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming Cancer Cell 22, 66-79 10.1016/j.ccr.2012.05.016
7. Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., Brock, M. V., and Biswal, S. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med. 3, e420 10.1371/journal.pmed.0030420
8. Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., Sougnez, C., Auclair, D., Lawrence, M. S., Stojanov, P., Cibulskis, K., Choi, K., de Waal, L., Sharifnia, T., Brooks, A., Greulich, H., Banerji, S., Zander, T., Seidel, D., Leenders, F., Ansen, S., Ludwig, C., Engel-Riedel, W., Stoelben, E., Wolf, J., Goparju, C., Thompson, K., Winckler, W., Kwiatkowski, D., Johnson, B. E., Janne, P. A., Miller, V. A., Pao, W., Travis, W. D., Pass, H. I., Gabriel, S. B., Lander, E. S., Thomas, R. K., Garraway, L. A., Getz, G., and Meyerson, M. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150, 1107-1120 10.1016/j.cell.2012.08.029
9. Hammerman, P. S., Hayes, D. N., Wilkerson, M. D., Schultz, N., Bose, R., Chu, A., Collisson, E. A., Cope, L., Creighton, C. J., Getz, G., Herman, J. G., Johnson, B. E., Kucherlapati, R., Ladanyi, M., Maher, C. A., Robertson, G., Sander, C., Shen, R., Sinha, R., Sivachenko, A., Thomas, R. K., Travis, W. D., Tsao, M. S., Weinstein, J. N., Wigle, D. A., Baylin, S. B., Govindan, R., and Meyerson, M. (2012) Comprehensive genomic characterization of squamous cell lung cancers Nature 489, 519-525 10.1038/nature11404
10. Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., and Hirohashi, S. (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. U. S. A. 105, 13568-13573 10.1073/pnas.0806268105
11. Muscarella, L. A., Barbano, R., D'Angelo, V., Copetti, M., Coco, M., Balsamo, T., la Torre, A., Notarangelo, A., Troiano, M., Parisi, S., Icolaro, N., Catapano, D., Valori, V. M., Pellegrini, F., Merla, G., Carella, M., Fazio, V. M., and Parrella, P. (2011) Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome Epigenetics 6, 317-325 10.4161/epi.6.3.14408
12. Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., Shibata, T., Yamamoto, M., and Hirohashi, S. (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68, 1303-1309 10.1158/0008-5472.CAN-07-5003
13. Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., and Hirohashi, S. (2008) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 135, 1358-1368.e4 10.1053/j.gastro.2008.06.082
14. Ooi, A., Wong, J. C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W., Tan, M. H., Zhang, Z., Yang, X. J., Zhou, M., Gardie, B., Molinie, V., Richard, S., Tan, P. H., Teh, B. T., and Furge, K. A. (2011) An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma Cancer Cell 20, 511-523 10.1016/j.ccr.2011.08.024
15. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S. D., Willis, J., Dawson, D., Willson, J. K., Gazdar, A. F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B. H., Bachman, K. E., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., and Velculescu, V. E. (2006) The consensus coding sequences of human breast and colorectal cancers Science 314, 268-274 10.1126/science.1133427
16. Jiang, T., Chen, N., Zhao, F., Wang, X. J., Kong, B., Zheng, W., and Zhang, D. D. (2010) High levels of Nrf2 determine chemoresistance in type II endometrial cancer Cancer Res. 70, 5486-5496 10.1158/0008-5472.CAN-10-0713
17. Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., Wong, P. K., and Zhang, D. D. (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 29, 1235-1243 10.1093/carcin/bgn095
18. Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., Gabrielson, E., Feinstein, E., and Biswal, S. (2008) RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy Cancer Res. 68, 7975-7984 10.1158/0008-5472.CAN-08-1401
19. Shibata, T., Kokubu, A., Saito, S., Narisawa-Saito, M., Sasaki, H., Aoyagi, K., Yoshimatsu, Y., Tachimori, Y., Kushima, R., Kiyono, T., and Yamamoto, M. (2011) NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer Neoplasia 13, 864-873 10.1593/neo.11750
20. Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., and Biswal, S. (2010) Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth Mol. Cancer Ther. 9, 336-346 10.1158/1535-7163.MCT-09-0589
21. Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., Minna, J. D., Stewart, D. J., and Wistuba, II. (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features Clin. Cancer Res. 16, 3743-3753 10.1158/1078-0432.CCR-09-3352
22. DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., Scrimieri, F., Winter, J. M., Hruban, R. H., Iacobuzio-Donahue, C., Kern, S. E., Blair, I. A., and Tuveson, D. A. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475, 106-109 10.1038/nature10189
23. Konstantinopoulos, P. A., Spentzos, D., Fountzilas, E., Francoeur, N., Sanisetty, S., Grammatikos, A. P., Hecht, J. L., and Cannistra, S. A. (2011) Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer Cancer Res. 71, 5081-5089 10.1158/0008-5472.CAN-10-4668
24. Singh, A., Bodas, M., Wakabayashi, N., Bunz, F., and Biswal, S. (2010) Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance Antioxid. Redox Signaling 13, 1627-1637 10.1089/ars.2010.3219
25. Prochaska, H. J. and Santamaria, A. B. (1988) Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers Anal. Biochem. 169, 328-336 10.1016/0003-2697(88)90292-8
26. Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M., and Biswal, S. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray Cancer Res. 62, 5196-5203
27. Lee, J. M., Moehlenkamp, J. D., Hanson, J. M., and Johnson, J. A. (2001) Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells Biochem. Biophys. Res. Commun. 280, 286-292 10.1006/bbrc.2000.4106
28. Kratschmar, D. V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C. E., and Odermatt, A. (2012) Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells PLoS One 7, e36774 10.1371/journal.pone.0036774
29. Ki, S. H., Cho, I. J., Choi, D. W., and Kim, S. G. (2005) Glucocorticoid receptor (GR)-associated SMRT binding to C/EBPbeta TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression Mol. Cell. Biol. 25, 4150-4165 10.1128/MCB.25.10.4150-4165.2005
30. Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., and Austin, C. P. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries Proc. Natl. Acad. Sci. U. S. A. 103, 11473-11478 10.1073/pnas.0604348103
31. Singh, A., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., Boros, L. G., Gonzalez, F. J., Gabrielson, E., Wong, K. K., Girnun, G., Biswal, S., and Happel, C. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis J. Clin. Invest. 123, 2921 10.1172/JCI66353
32. Abazeed, M. E., Adams, D. J., Hurov, K. E., Tamayo, P., Creighton, C. J., Sonkin, D., Giacomelli, A. O., Du, C., Fries, D. F., Wong, K. K., Mesirov, J. P., Loeffler, J. S., Schreiber, S. L., Hammerman, P. S., and Meyerson, M. (2013) Integrative radiogenomic profiling of squamous cell lung cancer Cancer Res. 73, 6289-6298 10.1158/0008-5472.CAN-13-1616
33. Bollong, M. J., Yun, H., Sherwood, L., Woods, A. K., Lairson, L. L., and Schultz, P. G. (2015) A Small Molecule Inhibits Deregulated NRF2 Transcriptional Activity in Cancer ACS Chem. Biol. 10, 2193-2198 10.1021/acschembio.5b00448
34. Kwak, M. K., Itoh, K., Yamamoto, M., and Kensler, T. W. (2002) Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter Mol. Cell. Biol. 22, 2883-2892 10.1128/MCB.22.9.2883-2892.2002
35. Singh, A., Wu, H., Zhang, P., Happel, C., Ma, J., and Biswal, S. (2010) Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype Mol. Cancer Ther. 9, 2365-2376 10.1158/1535-7163.MCT-10-0108
36. Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., and Zhang, D. D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism Proc. Natl. Acad. Sci. U. S. A. 108, 1433-1438 10.1073/pnas.1014275108
37. Hall, I. H., Lee, K. H., Elgebaly, S. A., Imakura, Y., Sumida, Y., and Wu, R. Y. (1979) Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells J. Pharm. Sci. 68, 883-887 10.1002/jps.2600680726